Searched for
KEWAL HANDA
Biosimilars offering a great opportunity in growing market: Kewal HandaThe prices have really been coming down in terms of raw materials and particularly in APIs. There is a lot of stability there. China are al...- Where to invest within the pharma theme? Industry expert Kewal Handa answersIndian per capita income increase will lead to increased spending on healthcare and medicines, including both generic and non-generic produ...
- Buy Greaves Cotton, target price Rs 183: Sharekhan by BNP ParibasGreaves Cotton., incorporated in the year 1922, is a Mid Cap company (having a market cap of Rs 2921.16 Crore) operating in Engineering sec...
- Mylan deal to give a boost to Pfizer’s India business: AnalystsOn Monday, Pfizer and Mylan announced that as per the Reverse Morris Trust transaction, each Mylan share would be converted into one share ...
- Trump healthcare policy not bad for Indian generics, but price may be a worry: Kewal Handa"If you follow Trump's vision, then it makes sense to have companies in the US and enjoy the benefits."
- Government needs proactive approach to boost pharma sector: IndustryThe Indian pharmaceutical industry, with current market size of USD 27.57 billion is expected to reach USD 55 billion by 2020 growing at a ...
- This time things could slightly different: Kewal Handa, Former MD, Pfizer"I see lot of Indian companies strengthening their business in US because the challenge again is in Russia," said Handa.
- US needs Indian generic products and India needs US: Kewal Handa, former MD at Pfizer LimitedAlmost one-third of Hillary’s expenses for elections are funded by the pharmaceutical companies with the hope that they can swing to our si...
- Heritage brands like Combiflam, Liv-52, Benadryl and others big earners in pharmaDrugs launched over 20 yrs ago remain money-spinners in the Indian pharma mkt because of strong brand recall and better access in smaller c...
- Pfizer growing above industry average: Kewal Handa, PfizerHopefully, with the Budget being very positive and hopefully with some reform measures announced, we will see some uptake and we will see h...
- Pharma buy-outs by MNCs will not result in price hikes: PfizerPfizer today allayed concerns that acquisition of Indian pharmaceutical firms by multinationals will lead to an increase in drug prices.
- Inflation, lack of funds to hit Indian pharma sectorLack of funds and buying power, resulting from soaring inflation and high cost of borrowing are likely to cause hurdle in growth of pharmac...
- Healthcare sector demands rollback of service taxPharma industry also fears imposition of MAT on Special Economic Zones would adversely impact their profits, since most export units of dru...
- Union Budget 2011: Increased excise duty, MAT on SEZs to hurt pharma industry'There is as expected nothing for the pharma industry, expect an increase in excise duty from 4 per cent to 5 per cent.'
- Pfizer launches penumonia-prevention vaccine Prevanar-13Global pharma major, Pfizer, on Thursday launched a new variant of pneumonia-prevention vaccine, Prevanar-13, in the Indian market.
- Pfizer to continue recruitment drivePfizer India will hire an additional 200 people in the next few months and will continue to increase its headcount because it sees minimal ...
- Pharma cos want new govt to boost spending, push reformsThe UPA government should scale up government spending on the pharma industry and it should also take measures conducive to research and de...
- India Inc wants more liquidity, rate cutNo doubt, the CRR cut is in the right direction, but companies are waiting for the lending rates to come down.
- Pfizer launches drug to help people quit smokingAiming to consolidate product portfolio in the Indian market, global pharma giant Pfizer on Thursday said it will introduce 2-3 more produc...
- Drug price control to hurt investments in India: MNCsThe Centre recently announced its intention to bring all 354 medicines on the National Lists of Essential Medicines under price control.
Load More
